Mutagenicity of the peroxisome proliferators clofibrate, Wyeth 14,643 and di-2-ethylhexyl phthalate in the lacZ plasmid-based transgenic mouse mutation assay

Journal of Carcinogenesis

Volumn 3, Issue , 2004, Pages

  Boerrigter, Michaël E T I ^a  

^a Leven Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CLOFIBRATE; DNA; GLYCOL; PEROXISOME PROLIFERATOR; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL SELECTION; CONTROLLED STUDY; DRUG DOSE REGIMEN; ESCHERICHIA COLI; EXPOSURE; FEMALE; GENE MUTATION; GENETIC TOXICOLOGY; HOST CELL; KIDNEY PARENCHYMA; LIVER PARENCHYMA; MALE; MOUSE; MUTAGENICITY; NONHUMAN; PLASMID; SPLEEN; TRANSGENIC MOUSE; WILD TYPE;

EID: 2942607413     PISSN: 14773163     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-3163-3-7     Document Type: Article

References (29)

1. International Agency for Research on Cancer: Peroxisome proliferation and its role in carcinogenesis: views and expert opinions of an IARC working group, Lyon, 7-11 December 1994. Lyon; 1995.
2. Roberts R, Moffat G, Ashby J: Exposure to peroxisome proliferators: reassessment of the potential carcinogenic hazard. Env Health Perspect 2001, 109:A462-A463.
3. Galloway SM, Johnson TE, Armstrong MJ, Ashby J: The genetic toxicity of the peroxisome proliferators class of rodent hepatocarcinogens.Mutat Res 2000, 448:153-158.
4. Ashby J, Brady A, Elcombe CR, Elliot BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IFH: Mechanistically-based human hazard assessment of peroxisome proliferators-induced hepatocarcinogenesis. Hum Exp Toxicol 1994, 13:S1-S117.
5. Hasmall SC, James NH, MacDonald N, Soames AR, Roberts RA: Species differences in response to diethylhexylphthalate: suppression of apoptosis, induction of DNA synthesis and peroxisone proliferator activated receptor alpha-mediated gene expression. Arch Toxicol 2000, 74:85-91.
6. Williams GM, Perrone C: Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. In: Peroxisomes: Biology and Role in Toxicology and Disease. Volume 84. Edited by Reddy JK. New York: New York Academy of Sciences; 1995:554-572.
7. Shane BS, Smith-Dunn DL, Ganesh L, Cunningham ML: Mutagenicity of Wyeth 14,643 in vivo in the liver of Big Blue transgenic mice [abstract]. Proc Am Assoc Cancer Res 1999, 39:241.
8. Deutsch WA, Kukreja A, Shane B, Hegde V: Phenobarbital, oxazepam and Wyeth 14,643 cause DNA damage as measured by the Comet assay. Carcinogenesis 2001, 16:439-442.
9. Piegorsch WW, Lockhart, A-MC, Margolin BH, Tindall KR, Gorelick NJ, Short, JM, Carr GJ, Thompson ED, Shelby MD: Sources of variability in data from a lacI transgenic mouse mutation assay. Environ Mol Mutagen 1994, 23:17-31.
10. Boerrigter METI, Vijg J: Sources of variability in mutant frequency determinations in different organs of lacZ plasmid-based transgenic mice: experimental features and statistical analysis. Environ Mol Mutagen 1997, 29:221-229.
11. Boerrigter METI: Treatment of lacZ plasmid-based transgenic mice with benzo[a]pyrene: measurement of DNA adduct levels, mutant frequencies, and mutant spectra. Environ Mol Mutagen 1999, 34:140-147.
12. Singh VK, Ganesh L, Cunningham ML, Shane BS: Comparison of the mutant frequencies and mutation spectra of three non-genotoxic carcinogens, oxazepam, Phenobarbital, and Wyeth 14,643, at the lambda cII locus in Big Blue transgenic mice. Biochem Pharmacol 2001, 62:685-692.
13. Boerrigter METI, Dolle MET, Martus, H-J, Gossen JA, Vijg J: Plasmid-based transgenic mouse model for studying in vivo mutations. Nature (London) 1995, 377:657-659.
14. Heddle JA, Dean S, Nohmi T, Boerrigter METI, Caciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus, H-J, Skopek TR, Thybaud V, Tindall KR, Yajima N: In vivo transgenic mutation assays. Environ Mol Mutagen 2000, 35:253-259.
15. Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman BW, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus H-J, Mirsalis JC, Skopek TR, Suzuki T, Yajima N: In vivo transgenic mutation assays. Mutat Res 2003, 540:141-151.
16. Wolff T, Topinka J, Deml E, Oesterle D, Schwartz LR: Dose dependent induction of DNA adducts, gene mutations, and cell proliferation by the antiandrogenic drug cyproterone acetate in rat liver. Adv Exp Med Biol 2001, 500:687-696.
17. International Agency for Research on Cancer: Di(2-ethylhexyl)phthalate. IARC Monogr Eval Carcinog Risks Hum 2000, 77:41-148.
18. International Agency for Research on Cancer: Monogr Eval Carcinog Risks Hum 1996, 66:391-412.
19. Gold LS, Zeiger E: Handbook of Carcinogenic Potency and Genotoxicity Databases. Boca Raton: CRC Press; 1997.
20. Marsman DS, Cattley RC, Conway JG, Popp JA: Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) in rats. Cancer Res 1988, 48:6739-6744.
21. Lundgren B, DePierre JW: Proliferation of peroxisomes and induction of cytosolic and microsomal epoxide hydrolases in different strains of mice and rats after dietary treatment with clofibrate. Xenobiotica 1989, 19:867-881.
22. Eastin WC, Mennear JH, Tennant RW, Stoll RE, Branstetter DG, Bucher JR, McCullough B, Binder RL, Spalding JW, Mahler JF: Tg.AC genetically altered mouse: assay working group overview of available data. Toxicologic Pathology 2001, 29:60-80.
23. Usui T, Mutai M, Hisada S, Takoaka M, Soper KA, McCullough B, Alden C: CB6F1-rasH2 mouse: overview of available data. Toxicologic Pathology 2001, 29:90-108.
24. +/- hemizygous knockout mouse: overview of available data. Toxicologic Pathology 2001, 29:30-50.
25. +/- knockout mice: overview of available data. Toxicologic Pathology 2001, 29:117-127.
26. Mauthe RJ, Gibson DP, Bunch RT, Custer L: The Syrian Hamster Embryo (SHE) cell transformation assay: review of the methods and results. Toxicologic Pathology 2001, 29:138-146.
27. Tsutsui T, Watanabe E, Barrett JC: Ability of peroxisome proliferators to induce cell transformation, chromosome aberrations and peroxisome proliferation in cultured Syrian hamster cells. Carcinogenesis 1993, 14:611-618.
28. Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y: Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl)phthalate, aluminium clofibrate and simfibrate. Cancer Lett 1990, 53:33-38.
29. Qu B, Li QT, Wong KP, Ong CN, Halliwell B: Mitochondrial damage by the "prooxidant" peroxisomal proliferators clofibrate. Free Radic Biol Med 1999, 27:1095-1102.